πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Reneo Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

CY6463

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious CNS diseases, with products like CY6463 for mitochondrial encephalomyopathy and Alzheimer's disease.

Tags: CNS diseases, CY6463, biopharmaceutical, clinical-stage, therapy development

Symbol: CYCN

Recent Price: $3.45

Industry: Biotechnology

CEO: Dr. Regina Graul Ph.D.

Sector: Healthcare

Employees: 1

Address: 245 First Street, Cambridge, MA 02142

Phone: 857 327 8778

Last updated: 2024-12-31

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ZYESAMI, NRX-100, NRX-101

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

Tags: CNS disorders, COVID-19 treatment, bipolar depression, clinical-stage pharmaceutical, pulmonary diseases, suicidal behavior

Symbol: NRXP

Recent Price: $1.53

Industry: Biotechnology

CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Sector: Healthcare

Employees: 2

Address: 1201 Orange Street, Wilmington, DE 19801

Phone: 484 254 6134

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Coherus BioSciences, Inc.

Coherus BioSciences, Inc. logo
Market Cap: Low
Employees: Low

UDENYCA

Coherus Bio Sciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. It markets UDENYCA and develops various biosimilar and immuno-oncology products.

Tags: Toripalimab, UDENYCA, biopharmaceutical, biosimilars, immuno-oncology

Symbol: CHRS

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Dennis M. Lanfear

Sector: Healthcare

Employees: 306

Address: 333 Twin Dolphin Drive, Redwood City, CA 94065

Phone: 650 649 3530

Last updated: 2024-12-31

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELX-02

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.

Tags: ELX-02, biopharmaceutical, clinical trials, cystic fibrosis, nephropathic cystinosis, rare diseases, ribosome modulation

Symbol: ELOX

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Sumit Aggarwal M.B.A.

Sector: Healthcare

Employees: 18

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 781 577 5300

Last updated: 2024-12-31

FibroGen, Inc.

FibroGen, Inc. logo
Market Cap: Lowest
Employees: Medium

Roxadustat, Pamrevlumab

Fibro Gen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics to treat serious unmet medical needs, including treatments for anemia, idiopathic pulmonary fibrosis, and Duchenne muscular dystrophy.

Tags: anemia, antibody, biopharmaceutical, cancer, kidney disease, pulmonary fibrosis, therapeutics

Symbol: FGEN

Recent Price: $0.53

Industry: Biotechnology

CEO: Mr. Thane Wettig

Sector: Healthcare

Employees: 486

Address: 409 Illinois Street, San Francisco, CA 94158

Phone: 415 978 1200

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

ANA001

A clinical-stage biotechnology company developing therapies for neurodegenerative, infectious, and cardiometabolic diseases.

Tags: biotechnology, cardiometabolic diseases, clinical trials, infectious diseases, neurodegenerative diseases

Symbol: NRBO

Recent Price: $2.36

Industry: Biotechnology

CEO: Mr. Hyung-Heon Kim

Sector: Healthcare

Employees: 8

Address: 200 Berkeley Street, Boston, MA 02116

Phone: 857 702 9600

Last updated: 2024-12-31

Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

Diazoxide Choline Controlled-Release

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, including their lead candidate for Prader-Willi Syndrome.

Tags: Prader-Willi Syndrome, biopharmaceutical, clinical-stage, rare diseases, therapeutics

Symbol: SLNO

Recent Price: $45.30

Industry: Biotechnology

CEO: Dr. Anish Bhatnagar M.D.

Sector: Healthcare

Employees: 33

Address: 203 Redwood Shores Parkway, Redwood City, CA 94065

Phone: 650 213 8444

Last updated: 2024-12-31

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Gene Therapies

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.

Tags: Biotechnology, Clinical Stage, Gene Therapy, Healthcare, Rare Diseases

Symbol: RCKT

Recent Price: $12.03

Industry: Biotechnology

CEO: Dr. Gaurav D. Shah M.D.

Sector: Healthcare

Employees: 268

Address: 9 Cedarbrook Drive, Cranbury, NJ 08512

Phone: 609 659 8001

Last updated: 2024-12-31

Renovaro Biosciences Inc.

Renovaro Biosciences Inc. logo
Market Cap: Lowest
Employees: Lowest

RENB-HV-01, RENB-HV-12, RENB-HB-01, RENB-DC-11, RENB-DC-12-XX, RENB-HV-21

Renovaro Biosciences Inc. is a pre-clinical stage biotechnology company focused on R&D of pharmaceutical and biological products for treating HIV, HBV, and cancer in the U.S. The company has a robust product pipeline and strategic partnerships, and was formerly known as Enochian Biosciences, Inc.

Tags: HBV treatment, HIV treatment, biotechnology, cancer treatment, pharmaceutical research, strategic partnerships

Symbol: RENB

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. David H. Weinstein

Sector: Healthcare

Employees: 25

Address: 2080 Century Park East, Los Angeles, CA 90067

Phone: 305 918 1980

Last updated: 2024-12-31

RenovoRx, Inc.

RenovoRx, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renovo Gem

Renovo Rx, Inc. is a clinical-stage biopharmaceutical company focusing on developing therapies for the treatment of solid tumors, with its lead product candidate, Renovo Gem, in Phase III clinical trials for locally advanced pancreatic cancer.

Tags: Renovo Gem, biopharmaceutical, clinical trials, pancreatic cancer, solid tumors

Symbol: RNXT

Recent Price: $1.39

Industry: Biotechnology

CEO: Mr. Shaun R. Bagai

Sector: Healthcare

Employees: 8

Address: 4546 El Camino Real, Los Altos, CA 94022

Phone: 650 284 4433

Leadership

  • Shaun R. Bagai, Director and Chief Executive Officer
  • Ramtin Agah, MD, Chairman, Chief Medical Officer, and Founder
  • Leesa Gentry, Chief Clinical Officer
  • Ronald B. Kocak, CPA, VP Controller and Principal Accounting Officer
  • Ryan Witt, Senior Vice President, Head of Corporate Strategy and Partnerships
  • Imtiaz Qureshi, MD, Director of Imaging
  • Angela Macfarlane, CEO of Perceive Biotherapeutics, Inc.
  • Laurence J. Marton, MD, Director
  • Una S. Ryan, PhD, OBE, Director
  • Robert J. Spiegel, Director

Last updated: 2024-12-31

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Medium

REC-994

Recursion Pharmaceuticals is a clinical-stage biotechnology company focusing on decoding biology to industrialize drug discovery, integrating technological innovations across multiple disciplines.

Tags: automation, biology, biotechnology, chemistry, clinical-stage, data science, drug discovery, engineering

Symbol: RXRX

Recent Price: $6.77

Industry: Biotechnology

CEO: Dr. Christopher C. Gibson Ph.D.

Sector: Healthcare

Employees: 500

Address: 41 South Rio Grande Street, Salt Lake City, UT 84101

Phone: 385 269 0203

Last updated: 2024-12-31

Rezolute, Inc.

Rezolute, Inc. logo
Market Cap: Low
Employees: Lowest

RZ358

Rezolute, Inc. is a clinical stage biopharmaceutical company focused on developing transformative therapies for metabolic diseases related to chronic glucose imbalance. Its lead product, RZ358, is aimed at treating congenital hyperinsulinism.

Tags: biopharmaceutical, clinical stage, congenital hyperinsulinism, genetic disorder, glucose imbalance, metabolic diseases

Symbol: RZLT

Recent Price: $4.89

Industry: Biotechnology

CEO: Mr. Nevan Charles Elam J.D.

Sector: Healthcare

Employees: 59

Address: 201 Redwood Shores Parkway, Redwood City, CA 94065

Phone: 650 206 4507

Last updated: 2024-12-31

Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

ENTR-601-44

Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.

Tags: Duchenne muscular dystrophy, EEV therapeutics, biotechnology, myotonic dystrophy type 1, neuromuscular diseases

Symbol: TRDA

Recent Price: $17.37

Industry: Biotechnology

CEO: Mr. Dipal Doshi

Sector: Healthcare

Employees: 168

Address: 6 Tide Street, Boston, MA 02210

Phone: 857 520 9158

Last updated: 2024-12-31

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Renazorb, UNI 494

Unicycive Therapeutics is a biotech company developing novel therapies for kidney diseases in the United States, focusing on treatments for hyperphosphatemia and acute kidney injury.

Tags: Renazorb, UNI 494, acute kidney injury, biotechnology, hyperphosphatemia, kidney diseases

Symbol: UNCY

Recent Price: $0.58

Industry: Biotechnology

CEO: Dr. Shalabh K. Gupta M.D., MPA

Sector: Healthcare

Employees: 14

Address: 4300 El Camino Real, Los Altos, CA 94022

Phone: 650 351 4495

Last updated: 2024-11-08

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31